Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been reported to induce antitumor activity in peripheral blood monocytes. We examined the role of GM-CSF on bone marrow (BM) macrophages in inducing antibody-dependent cellular cytotoxicity (ADCC) against murine and human tumor cells in vitro and in vivo with the aim of applying this approach in an autologous bone marrow transplantation (BMT) setting. GM-CSF induced a potent ADCC in BM macrophages against a murine melanoma in vitro. Treatment with GM-CSF alone or with antibody alone had no effect, whereas therapy with combination of both these agents resulted in a significant reduction in dissemination of melanoma both in a nontransplant as well as in BMT settings, with results being more optimal in
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UTOLOGOUS bone marrow transplantation (ABMT)
A is followed by a high relapse rate possibly because the procedure lacks the inherent graft-versus-tumor effect present in allogeneic BMT.',' Recent approaches to induce a graft-versus-tumor effect in ABMT have focused on modulation of T-cell functions. These have included the use of cyclosporine A, interleukin-2, interferon, and a combination of cyclosponne A and interle~kin-2.~-' Analysis of the data from these reports suggests that those and other novel strategies are required to improve the survival of the tumor-bearing hosts undergoing ABMT.
Macrophages have been known to play an important role in the host defense against cancer.' Activated macrophages both from normal persons as well as tumor-bearing hosts demonstrate potent antitumor effect both in vitro and in V~V O .~~'~ Several cytokines, including interleukin-2, interferon, and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been reported to mediate antibody-dependent cellular cytotoxicity (ADCC) via stimulation of macrophages. ' '-I4
Another novel strategy aimed to eradicate the tumor is the use of monoclonal antibodies (MoAbs)." However, the success with MoAb therapy alone has been limited by variable expression of antigens on the tumor cell surface, the non-availability of suitable antibodies, and the inability of the latter setting. Adoptive transfer of BM macrophages harvested from mice undergoing therapy with GM-CSF plus antibody significantly reduced the dissemination of melanoma in secondary recipients but only after irradiation, not in intact mice. GM-CSF also induced significant ADCC in human BM macrophages against a melanoma and a lymphoma in vitro and against a lymphoma implanted in nude mice in vivo. Again, these effects were more optimal after chemotherapy. These data suggest that treatment with GM-CSF plus tumor-specific monoclonal antibodies after BMT may induce an antitumor effect and help eradicate the minimal residual disease. the antibody to attain optimal concentration at every tumor site.
The present study has been carried out to define the role of GM-CSF in inducing ADCC in bone marrow (BM) macrophages. Application of this approach in ABMT could achieve more effective elimination of the tumor because the tumor load is at its minimum following preparative therapy for ABMT. In addition, the uptake of the MoAb by the tumor has been reported to increase following irradiation.16
MATERIALS AND METHODS
Each in vitro and in vivo experiment was camed out three times. For in vivo studies, there were always four mice under each treatment arm. A control group that received no treatment was included in every experiment.
Tumor cells. Tumor cell lines B16 (a murine melanoma), Raji (human lymphoma), and A375 (human melanoma) were obtained from the American Type Culture Collection (Rockville, MD) and propagated in culture medium (CM) consisting of RPMI I640,O. 1 mmol/L nonessential amino acids, 1 mmol/L sodium pyruvate, and 0.03% L-glutamine (Irvine Scientific, Santa Ana, CA), 5 X IO-' mol/L 2-mercaptoethanol (Sigma, St Louis, MO), penicillin (100 p/mL), streptomycin (100 pg/mL). and 10% heat-activated fetal calf serum (FCS) (JR Scientific, Woodland, CA). The cells were cryopreserved with 10% dimethylsulfoxide (Sigma) in 90% FCS at -80°C. They were thawed and allowed to grow in CM at 37°C with 5% C 0 2 in air in a humid atmosphere for 24 hours before use. For establishing B16 melanoma in vivo, 2 X IO5 cells were injected intravenously (IV) in a volume of 0.5 mL. The Raji tumor was established by injecting lO'cells on the left thigh ofthe nude mice in a volume of 50 pL. Before in vivo use, the tumor cells were washed three times with RPMI and finally suspended appropriately in RPMI.
The animals used in this study were intact C57BL/6 and nude BALB/c female mice between the ages of 8 and 12 weeks. They were obtained from Jackson Laboratory (Bar Harbor, ME For activation in vitro, whole BM or BM macrophages were placed in CM ( lo6 cells/mL) with different concentrations of GM-CSF for variable periods of time at 37°C in a humid atmosphere with 5% C 0 2 in air. The cells were harvested with cell scrapers and used as effectors in cytotoxicity assays. For in vivo use, the activated cells were washed three times with RPMI and resuspended in RPMI to infuse 5 X lo6 cells/mouse IV in a volume of 0.5 mL.
Reagents. Recombinant human and murine GM-CSF were obtained from Genzyme Corporation (Boston, MA). Antibody to B 16 murine melanoma was an IgG2a antibody (a kind gift of Dr Avi Eisenthal, Surgery Branch, NIH, Bethesda, MD). Lym-1, an IgGl MoAb against human B-cell lymphoma was generously provided by Dr Allan Epstein. ZME, an IgG2a MoAb was provided by Hybritech Corp (San Diego, CA). 3G8, an Fc-receptor antibody developed by Jay Unkeless was provided by Dr Dixon Gray ofthe University of Southern California, Los Angeles. Carrageenan was obtained from Sigma. For endogenous depletion of macrophages, it was administered in a dose of 60 mg/kg of body weight intraperitoneally (IP) for 4 consecutive days starting on the day of treatment.
Chromium release assay. The in vitro cytotoxic potential of BM/macrophages activated with GM-CSF was tested in an 18-hour chromium release assay. The tumor cells (IO6) were labeled with 400 pCi of NaCrO, (ICN Radiochemical, Irvine, CA) for I hour. The cells were washed three times with CM and placed at a concentration of 5 X IO3 cells/well in 96-well round-bottomed microtiter plates (Corning). Relevant or irrelevant antibody and various numbers of effector cells were added in a final volume of 200 pL/well. Maximum isotope release was ensured by addition of 0.1 N HCI to the target cells while spontaneous release was allowed by addition of CM. The plates were incubated at 37°C for 18 hours. The culture supernatant was harvested with the Skatron Titertek System (Skatron AS Libergyen, Lier, Norway) and counted in a gamma counter (Packard Auto Gamma-500; United Technologies Packard, Laguna Hills, CA). The percentage of specific lysis was calculated by the formula:
Experimental cpm -Spontaneous cpm Maximum cpm -Spontaneous cpm All determinations were made in triplicate and data were calculated as mean k SEM. Lytic units (LU) were calculated by a computer program as described before" and expressed as LU/ lo7 effector cells causing lysis of 30% of the targets.
Treatment/BMT. Treatment with GM-CSF and/or an MoAb was started at variable time points after establishing the tumor. BMT was performed on day 3 after induction of tumor. The cytoreductive regimen for BMT comprised cyclophosphamide (BristolMyers, Evansville, IN) 100 mg/kg body weight IP, followed 4 hours later by 500 rad of total body irradiation (TBI) delivered at a rate of 130 rad/min from a Ganmmacel cesium irradiator (Atomic Energy of Canada, Ottawa, Ontario).
Raji tumor cells ( 107/mouse) were injected intradermally on the left thigh of nude mice 24 hours after TBI (500 rad). They were administered cyclophosphamide, 50 mg/kg body weight, 2 days after inoculation of the tumor. BM cells were infused (5 X lo6 cells/mouse IV) 8 to 10 hours after cyclophosphamide. Mice receiving fresh or activated macrophages (5 X 106/mouse IV) were infused with fresh BM ( 5 X 106/mouse) as well to enable reconstitution.
B16 melanoma-bearing mice were killed on day 21 postinduction of tumor. Their lungs were harvested and fixed in 70% ethyl alcohol; the pulmonary metastases of the melanoma were enumerated in a blinded manner. In some experiments, the response was evaluated by monitoring the survival of the tumor-bearing mice.
In Raji lymphoma-bearing mice, the response was monitored by measuring the largest diameter of the tumor-bearing limb at weekly intervals for 3 weeks after induction of tumor." B16-bearing mice were either subjected or not subjected to BMT on day 3 postinduction of tumor. They were infused on day 3 postinduction of tumor with macrophages (5 X 106/mouse IV) obtained from BM of another group of BI6-bearing mice that had received treatment with GM-CSF and MoAb; the BM from the donor mice was harvested immediately after completion of therapy. The mice receiving adoptive transfer of BM macrophages were killed on day 21 postinduction of tumor, and the pulmonary metastases in their lungs were enumerated.
Human BM. The human BM used in these studies belonged to nine patients. BM was collected from patients undergoing BM harvest for autologous BMT at the Noms Cancer Center, University of Southern California, Los Angeles, after an informed consent. BM was collected in medium 199 (GIBCO, Grand Island, NY) with preservative-free heparin (50 w/mL). Mononuclear cells were isolated by centrifuging the BM over Ficoll-Hypaque at 2,000 rpm for 20 minutes at 20°C; the interface cells were collected and washed twice with RPMI. The BM cells were cryopreserved with 10% dimethylsulfoxide in FCS at -80°C and thawed at the time of use. BM macrophages were isolated by the same method as used for isolation of macrophages from murine BM. Activation of human BM/macrophages with GM-CSF was performed in the same manner as described above for murine BM/macrophages.
There were no significant differences noted in the in vitro or in vivo results by using the BM from the different patients even though they varied in pretreatment and disease parameters.
Statistical analysis. Comparison of results in various groups was carried out by a two-sided log rank test?' The survival data have been analyzed by the Cox regression method.*' Evaluation os response.
Adoptive transfer studies.
RESULTS
The data have been pooled from three sets of observations. There was no significant interexperiment variability, and standard deviations were less than 10%. Data shown in Table 1 suggest that activation of whole BM or purified macrophages with GM-CSF induced a significant ADCC against a murine melanoma. GM-CSF or the antibody to B16 by themselves did not show any cytotoxicity. Activation of whole BM with GM-CSF always generated only slightly greater cytotoxicity than that by the monocytes, and, in fact, GM-CSF did not induce any ADCC in the BM depleted of macrophages.
The optimum concentration of GM-CSF and optimum duration of activation of BM macrophages were found to be 10 to 100 ng/mL and 3 days, respectively (Table 2 ). This assay was performed both holding the assay day and the day of set-up constant with similar results. In subsequent in vitro experiments, including those with human BM/macrophages,
Induction of ADCC by murine GM-CSF in vitro.

Kinetics of induction of ADCC by GM-CSF.
For Pvalues in both columns: groups 3 versus 4 , 5 versus 6, and groups 4 and 6 (antibody vs no antibody) P < .05 in each case. Data shown are % Cr5' release (mean + SEM) at end E:T ratio of 50: 1 .
Antibody added in the cytotoxicity wells at a concentration of 10 pg/mL without any effector cells.
t GM-CSF added in the cytotoxicity plates at a concentration of 100 ng/mL without any effector cells.
t Whole EM or macrophages cultured (106/mL) with GM-CSF (100 ng/mL) for 3 days.
these two parameters were used for induction of cytotoxicity.
Synergism of GM-CSF and MoAb to B16 in induction of antitumor effect in vivo.
Preliminary experiments were performed to determine the optimum time of institution of treatment with GM-CSF and or B 16 antibody after induction of B 16 melanoma in mice. These confirmed the in vitro findings that a 3-day pretreatment with GM-CSF before MoAb was optimal. Furthermore, 100 ng/mouse IP twice a day appeared to reproduce the in vitro findings.
In a nontransplant setting, GM-CSF alone or MoAb to B16 alone showed no effect against established B16 melanoma. However, a combination of GM-CSF and the MoAb resulted in significant reduction in the pulmonary metastases and prolongation of survival (Table 3) . Adoptive transfer of BM macrophages harvested from primary donor mice immediately after their completion of GM-CSF and antibody therapy resulted in a differential pattern of response in secondary recipients depending on whether the secondary mice had or had not received prior irradiation. They had no effect in recipients who had not had prior irradiation and chemotherapy as compared with untreated controls (pulmonary metastases 85 f 7 vs 88 k 4; P > .05).
However, in a BMT setting, (ie, where the secondary recipients had received prior irradiation and chemotherapy), adoptive transfer of macrophages resulted in a significant control of tumor dissemination as compared with BMT alone (pulmonary metastases 54 t 6 vs 83 f 7; P < .05). Adoptive transfer of BM macrophages from primary donors who were untreated had no effect. BMT alone did not reduce the dissemination of B 16 melanoma. Combined treatment with GM-CSF and MoAb again resulted in a significant reduction in pulmonary metastases and prolongation of survival of tumor-bearing mice ( Table 4 ). The effects of GM-CSF and MoAb seen in the BMT setting were far greater than in the nonirradiated or chemotherapy-treated mice. Administration of carrageenan after BMT led to a loss of antitumor effect of GM-CSF plus antibody ( Table 4) .
Induction ofADCC by human GM-CSF in human BMin vitro. The ZME antibody and melanoma cells were used here to determine the specificity of the ADCC. Recombinant human GM-CSF induced significant ADCC in human BM and BM macrophages against human lymphoma (Raji) and a melanoma (A375) cells in the presence of Lym-1 and ZME MoAb, respectively. It is important to note that GM-CSF did not induce any killing of Raji cells by the BM macrophages in the presence of ZME or that of melanoma cells in the presence of Lym-1 ( Table 5 ). This suggests that the ADCC induced by GM-CSF was not a nonspecific kill- EM macrophages isolated from murine BM were tested either without or after stimulation with different concentrations of GM-CSF for variable duration of time against 81 6 melanoma in a 5'Cr release assay. Pvalues between 100 ng/mL GM-CSF versus the other concentrations and 3 days versus the other durations are < .05 both with and without antibody.
BM macrophages kept in culture (lo6 cells/mL) with indicated concentrations of GM-CSF for 3 days.
t BM macrophages cultured for indicated duration with GM-CSF (1 00 ng/mL).
C57 BL/6 mice were infused with B1 6 cells (2 x 1 05/mouse) IV and treated variously. Control groups received no treatment. P values: in both columns, groups 1 versus 2 versus 3, P = .64; group 4 versus all other groups, P < .01.
* GM-CSF was administered in a dose of 100 ng/mouse IP twice a day from days 3 through 8 postinduction of tumor.
t Antibody to E16 was administered (100 pg/mouse) IP on days 6
and E postinduction of tumor.
* Mice were either killed on day 21 for enumeration of pulmonary metastases or were followed for survival. Data are shown as mean * SE.
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MoAbs. Increased concentration of the antibodies at the tumor site has been reported following irradiation,I6 presumably because of the vascular change^.'^,^^ In addition, tumor cells exposed to chemotherapeutic agents also exhibit increased susceptibility to cytotoxic cells?
Our study shows that GM-CSF alone or a tumor-specific antibody alone showed a modest effect, whereas a combination of the two induced significant killing of the tumor targets by both human as well as murine BM macrophages in vitro. Preliminary experiments showed that GM-CSF-induced ADCC could not be blocked by antibodies to tumor necrosis factor, interleukin-1, or class I or class I major histocompatibility antigens. Also, in preliminary experiments, the use of purified human macrophages also duplicated this antitumor effect. Interestingly, the antitumor effect generated from whole BM was only slightly higher than that from purified macrophages. However, depletion of macrophages from the BM led to a complete loss ofthis effect. This points to an interaction between more than one cell population. It is probable that stimulation of BM macrophages by GM-CSF results in activation of another cell population, possibly lymphocyte^,'^ resulting in a cumulative antitumor response. Alternatively, stimulation of lymphocytes may increase the macrophage effector activation. GM-CSF has also been reported to induce the secretion of interferon from monocytes.13 Interferon is a potent stimulus for augmentation of natural killer activity." Thus, it is possible that GM-CSF-induced ADCC was the result of a complex interaction of various cellular and humoral mechanisms. It is interesting in this regard that granulocyte colony-stimulating factor did not show a similar effect in our models (data not shown).
Our in vivo studies demonstrated that GM-CSF and MoAbs showed a significant synergism in controlling the C57 BL/6 mice were infused with B16 cells (2 X 1 05/mouse) IV and were subjected to BMT on day 3 postinduction of tumor. Control groups received no treatment. P values: in both columns, groups 1 versus 2 versus 3 versus 4 versus 6, P = .73; group 5 versus all other groups, P < ,001.
Mice were either killed on day 21 for enumeration of pulmonary metastases or were followed for survival. Data are shown as mean f SE. t GM-CSF was administered in a dose of 1 0 0 ng/mouse IP twice a day from days 3 through 8 postinduction of tumor.
$ Antibody to B16 was administered (100 pglmouse) IP on days 6 and 8 postinduction of tumor.
§ Animals in group 6 were treated as in group 5, but with the additional administration of carageenan 60 mg/kg IP on days 3 through 8 postinduction of tumor ing. Again, the cytotoxic potential ofwhole BM was slightly greater than that of purified macrophages. The GM-CSFinduced ADCC could be blocked by 3G8, an MoAb to the Fc receptor; thus, pointing to the ADCC nature of the induced killing.
GM-CSF induced a potent antitumor effect against a human lymphoma implanted in nude mice, but again, only on the background of prior treatment with cyclophosphamide (Table 6). GM-CSF and Lym-l by themselves had no activity in this setting.
Induction of ADCC by human GM-CSF in vivo. GM-CSF has been widely used following chemotherapy as well as autologous BMT with the aim of hastening myeloid recovery and reducing the complications related to severe n e~t r o p e n i a .~~, '~ Recent studies have shown that GM-CSF also induces cytotoxic potential in several cell populations, including neutrophils, lymphocytes, and monoc y t e~. '~, '~, '~ Because monocytes play an important role in defense against tumors, it is of interest to explore means of immunostimulation of these cells. GM-CSF-induced augmentation of cytotoxic function of monocytes has been reported both by its effect on direct (ie, antibody-independent) cytotoxicity as well as via ADCC.13, '4,25 We have been investigating approaches to immunomodulation of BM cells with the aim oftheir application in autologous BMT.7,'6 The institution of biotherapy in the immediate post-transplant period following autologous BMT could eradicate residual disease. Delay in the institution of such therapy leads to proliferation of the residual disease that is difficult to eradicate by immunotherapy." Autologous BMT also provides a suitable setting for treatment with
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No Effector Group Lym-l +Lym-1 ZME +ZME (1 P values comparing these two values with other values in their respective columns, P < .05 in each case. P values comparing all other values in their respective columns, P > .05. 1 1 BM was infused on day 10 postinduction of tumor; GM-CSF and Lym-1 were administered as described under footnotes t and $.
progression of both murine and human tumors. Interestingly, a combination of the two agents showed a much more potent activity in a BMT setting (ie, after irradiation of the host) even though the tumor (B16 melanoma) is resistant to chemotherapy and radiotherapy. This might have been because of increased concentration of the antibody at the tumor site.I6 Another mechanism that has been recently proposed suggests that chemotherapy and irradiation break the tolerance to the tumor resulting in its increased susceptibility to eradication by immune mechanism." Further studies are required to define the mechanisms involved in the GM-CSF-induced ADCC. In this regard, preliminary immunohistology of the tumors after treatment showed a mixed cellular infiltrate.
Effector cells generated secondary to cytokine therapy generally maintain their antitumor effect only as long as such therapy continue^.^' It is significant to note that in our studies, BM macrophages collected from mice undergoing GM-CSF plus antibody therapy maintained their antitumor effect in the secondary hosts in the absence of further therapy; again, only if the secondary host was treated with irradiation and chemotherapy. These observations suggest that immunomodulation of BM macrophages might maintain a potent antitumor effect ensuring the eradication of residual disease in an autologous BMT setting.
In conclusion, our data suggest that biotherapy with GM-CSF plus MoAb following autologous BMT may constitute a novel strategy in induction of a graft-versus-tumor effect and reducing the relapse rate.
